This study confirmed that LXR activation may also inhibit PAH-induced cardiac hypertrophy and remodeling, and one of the mechanisms may be inhibition of NF-κB -mediated inflammatory and apoptotic pathways. The gene discussed is NFKB1; the disease is cardiac hypertrophy.